Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients

Breast Cancer Research and Treatment

Volumn 144, Issue 1, 2014, Pages 143-152

  Wong, A L ^a,c   Seng, K Y ^b   Ong, E M ^a   Wang, L Z ^c   Oscar, H ^a   Cordero, M T ^a   Copones, R ^a   Fan, L ^b   Tan, S H ^a   Goh, B C ^a,b,c   Lee, S C ^a,c  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Body composition; Breast cancer; Doxorubicin pharmacokinetics; Doxorubicin toxicities; Inter ethnic variability

Indexed keywords

DOCETAXEL; DOXORUBICIN;

ADULT; ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASIAN; BLOOD TOXICITY; BODY COMPOSITION; BODY FAT; BODY SURFACE; BREAST METASTASIS; CANCER INCIDENCE; CANCER PATIENT; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; HUMAN; INTRAABDOMINAL FAT; LEUKOPENIA; LIPID COMPOSITION; MULTIPLE CYCLE TREATMENT; MUSCLE MASS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADIPOSE TISSUE; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BODY FAT DISTRIBUTION; BODY SURFACE AREA; DOXORUBICIN; FEMALE; HUMANS; LEUKOPENIA; MIDDLE AGED; NEUTROPENIA;

EID: 84894659147     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2843-8     Document Type: Article

References (31)

1. Ratain MJ (1998) Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 16:2297-2298
2. Gurney H (1996) Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 14:2590-2611
3. Miller AA (2002) Body surface area in dosing anticancer agents: scratch the surface! J Natl Cancer Inst 94:1822-1823
4. Baker SD, Verweij J, Rowinsky EK et al (2002) Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 94:1883-1888
5. Rodvold KA, Rushing DA, Tewksbury DA (1988) Doxorubicin clearance in the obese. J Clin Oncol 6:1321-1327
6. Thompson PA, Rosner GL, Matthay KK et al (2009) Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser pediatric research network study. Cancer Chemother Pharmacol 64:243-251
7. Frost BM, Eksborg S, Bjork O et al (2002) Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med Pediatr Oncol 38:329-337
8. Beith J, Goh BC, Yeo W et al (2002) Inter-ethnic differences in the myelotoxicity of adriamycin/cyclophosphamide (AC) for adjuvant breast cancer. Proc Am Soc Clin Oncol 21:252
9. Ma B, Yeo W, Hui P et al (2002) Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer: a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol 62:185-189
10. Fan L, Goh BC, Wong CI et al (2008) Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet Genomics 18:621-631
11. Sparreboom A, Wolff AC, Mathijssen RH et al (2007) Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25:4707-4713
12. Thibault R, Pichard C (2012) The evaluation of body composition: a useful tool for clinical practice. Ann Nutr Metab 60:6-16
13. Prado CM, Baracos VE, McCargar LJ et al (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13:3264-3268
14. Kyle UG, Morabia A, Slosman DO et al (2001) Contribution of body composition to nutritional assessment at hospital admission in 995 patients: a controlled population study. Br J Nutr 86:725-731
15. Mitsiopoulos N, Baumgartner RN, Heymsfield SB et al (1998) Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 85:115-122
16. Shen W, Punyanitya M, Wang Z et al (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 97:2333-2338
17. Kuk JL, Katzmarzyk PT, Nichaman MZ et al (2006) Visceral fat is an independent predictor of all-cause mortality in men. Obesity (Silver Spring) 14:336-341
18. Andersen A, Warren DJ, Slordal L (1993) A sensitive and simple high-performance liquid chromatographic method for the determination of doxorubicin and its metabolites in plasma. Ther Drug Monit 15:455-461
19. Wahlby U, Jonsson EN, Karlsson MO (2001) Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28:231-252
20. Prado CM, Lieffers JR, McCargar LJ et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629-635
21. Rosner GL, Hargis JB, Hollis DR et al (1996) Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 14:3000-3008
22. Chan KK, Cohen JL, Gross JF et al (1978) Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model. Cancer Treat Rep 62:1161-1171
23. Fisher B, Brown AM, Dimitrov NV et al (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496
24. Deurenberg-Yap M, Schmidt G, van Staveren WA, Deurenberg P (2000) The paradox of low body mass index and high body fat percentage among Chinese, Malays and Indians in Singapore. Int J Obes Relat Metab Disord 24:1011-1017
25. Wang J, Thornton JC, Russell M et al (1994) Asians have lower body mass index (BMI) but higher percent body fat than do whites: comparisons of anthropometric measurements. Am J Clin Nutr 60:23-28
26. Lear SA, Humphries KH, Kohli S et al (2007) Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT). Am J Clin Nutr 86:353-359
27. Prado CM, Baracos VE, McCargar LJ et al (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:2920-2926
28. Prado CM, Lima IS, Baracos VE et al (2011) An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 67:93-101
29. Sugioka N, Haraya K, Fukushima K et al (2009) Effects of obesity induced by high-fat diet on the pharmacokinetics of nelfinavir, a HIV protease inhibitor, in laboratory rats. Biopharm Drug Dispos 30:532-541
30. Lottenberg SA, Giannella-Neto D, Derendorf H et al (1998) Effect of fat distribution on the pharmacokinetics of cortisol in obesity. Int J Clin Pharmacol Ther 36:501-505
31. Nakao YM, Miyawaki T, Yasuno S et al (2012) Intra-abdominal fat area is a predictor for new onset of individual components of metabolic syndrome: MEtabolic syndRome and abdominaL ObesiTy (MERLOT study). Proc Jpn Acad Ser B Phys Biol Sci 88:454-461